Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer
Industry Supported Symposium

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives treatment selection, the importance of toxicity management, and strategies for sequencing therapies across patient subtypes. The session will conclude with forward-looking perspectives on addressing data gaps and improving outcomes.

Eisai has sponsored this initiative with IGCS and had no input into or influence over the content.

Target Audience

Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.

Learning Objectives

Upon completion of the activities in this series, learners will be able to:

• Differentiate endometrial cancer across molecular classifications in terms of biology, clinical behavior, and treatment outcomes.
• Evaluate current evidence and clinical considerations for treatment of, primary advanced and recurrent endometrial cancer.
• Discuss therapeutic sequencing strategies in advanced/recurrent endometrial cancer, especially in the context of disease progression.
• Apply real-world patient case scenarios to guide treatment decisions, manage toxicities, and address gaps in sequencing data.

Agenda

Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer, an Industry Supported Symposium presented at the IGCS 2025 Annual Global Meeting

This session is not included in the main event CME/CPD credit.

Access the Presentation Slides